ValuEngine upgraded shares of Hikma Pharmaceuticals Plc (OTC:HKMPF) from a hold rating to a buy rating in a report released on Thursday.

HKMPF has been the subject of a number of other research reports. Numis Securities Ltd reaffirmed an add rating on shares of Hikma Pharmaceuticals Plc in a research report on Friday, May 19th. Jefferies Group LLC downgraded shares of Hikma Pharmaceuticals Plc from a buy rating to an underperform rating in a research report on Wednesday, May 17th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. Hikma Pharmaceuticals Plc currently has a consensus rating of Hold and an average target price of $27.00.

Hikma Pharmaceuticals Plc (OTC HKMPF) opened at 18.40 on Thursday. Hikma Pharmaceuticals Plc has a 1-year low of $18.15 and a 1-year high of $35.25. The company has a 50-day moving average price of $20.48 and a 200 day moving average price of $23.62. The stock has a market cap of $4.43 billion and a P/E ratio of 27.79.

WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.